USANA Health Sciences (NYSE:USNA) Stock Price Down 6% – Should You Sell?

USANA Health Sciences, Inc. (NYSE:USNA)’s stock price was down 6% on Friday . The stock traded as low as $33.00 and last traded at $32.77. Approximately 68,031 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 116,075 shares. The stock had previously closed at $34.86.

Wall Street Analysts Forecast Growth

USNA has been the topic of several recent analyst reports. DA Davidson lifted their target price on USANA Health Sciences from $35.00 to $38.00 and gave the company a “neutral” rating in a research note on Thursday, January 2nd. StockNews.com raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 28th.

USANA Health Sciences Price Performance

The firm has a market cap of $623.36 million, a P/E ratio of 11.55, a PEG ratio of 0.94 and a beta of 0.89. The company’s 50 day moving average is $36.05 and its two-hundred day moving average is $38.21.

Insider Activity at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 675 shares of USANA Health Sciences stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.33% of the stock is currently owned by insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of USNA. Pzena Investment Management LLC grew its holdings in shares of USANA Health Sciences by 7.5% during the third quarter. Pzena Investment Management LLC now owns 1,049,610 shares of the company’s stock worth $39,801,000 after purchasing an additional 72,977 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of USANA Health Sciences by 8.8% during the fourth quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock worth $21,247,000 after purchasing an additional 47,745 shares during the period. State Street Corp lifted its holdings in shares of USANA Health Sciences by 0.6% during the 3rd quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after purchasing an additional 2,782 shares in the last quarter. Geode Capital Management LLC grew its position in shares of USANA Health Sciences by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock valued at $11,269,000 after purchasing an additional 12,898 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in USANA Health Sciences by 13.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock worth $4,702,000 after purchasing an additional 14,756 shares in the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.